Y mAbs Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $18,461 | $22,798 | $19,931 | $23,363 |
Gross Profit | 16,213 | 19,784 | 17,784 | 21,324 |
EBITDA | -8,447 | -9,636 | -6,749 | -3,038 |
EBIT | -8,568 | -9,789 | -6,908 | -3,199 |
Net Income | -6,998 | -9,249 | -6,629 | -988 |
Net Change In Cash | 18,461 | 22,798 | 19,931 | 23,363 |
Free Cash Flow | -10,665 | 298 | -3,477 | -8,036 |
Cash | 68,122 | 77,806 | 75,749 | 78,637 |
Basic Shares | 44,626 | 44,022 | 43,779 | 43,627 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $84,819 | $65,267 | $34,897 | $20,750 |
Gross Profit | 73,403 | 57,700 | 32,383 | 18,547 |
EBITDA | -25,672 | -93,972 | -114,651 | -119,539 |
EBIT | -26,407 | -94,811 | -115,433 | -119,935 |
Net Income | -21,427 | -96,325 | -56,345 | -118,343 |
Net Change In Cash | 84,819 | 65,267 | 34,897 | 20,750 |
Cost of Revenue | 66,801 | -92,012 | ||
Free Cash Flow | -27,232 | -75,921 | -103,523 | -91,406 |
Cash | 78,637 | 105,762 | 181,564 | 114,634 |
Basic Shares | 43,645 | 43,703 | 43,181 | 40,118 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.16 |
2024-06-30 | -$0.21 |
2024-03-31 | -$0.15 |
2023-12-31 | -$0.02 |
